Loading
Life sciences · Journal article
Frontiers in Endocrinology · September 3, 2026
Encouraging direction, but not yet definitive.
This study reports that Lactiplantibacillus pentosus CECT 8039 increases colonic short-chain fatty acid concentrations in vitro, enhances enteroendocrine hormone expression and release, and reduces body-weight gain and circulating adipokines in mice fed a high-fat diet over 28 days. The findings suggest a functional link between probiotic-modulated fermentation and metabolic pathways, but the authors acknowledge that direct causality and human relevance remain to be established.
In vitro dynamic multi-compartment colonic fermentation model and parallel murine high-fat diet intervention. In vitro: human fecal microbiota-seeded fermentation model and enteroendocrine/immune cell lines. In vivo: mice fed high-fat diet; specific strain, age, and sex not stated in abstract.. Intervention: Lactiplantibacillus pentosus CECT 8039 (L. pentosus BB) supplementation in fermentation model and in HFD-fed mice.. Compared with: Untreated fermentation (end of stabilization) and HFD-fed mice without probiotic supplementation..
Acetate, propionate, and butyrate concentrations increased 2.53-, 7.34-, and 5.08-fold respectively in the ascending colon after probiotic treatment. GLP-1 release increased significantly in transverse-colon fermentation condition; Pyy mRNA and Cck expression increased significantly in ascending and descending colon and all compartments respectively. HFD-fed mice showed 34.9 ± 5.5% body-weight gain; probiotic supplementation reduced relative body-weight gain by 13.2 ± 4.7%.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These preclinical findings suggest a mechanistic pathway by which this specific probiotic strain may modulate metabolic homeostasis in early obesity through SCFA production and enteroendocrine signaling. Clinical translation requires human trials to confirm efficacy, clarify SCFA-mediated causality, and address heterogeneous immune responses.
A mechanistically-informed in vitro and animal study showing consistent metabolic and enteroendocrine effects of a specific probiotic strain in diet-induced obesity, but limited to mouse models and requiring confirmation in humans.
As stated by the source record.
Quoted from the source exactly as published.
These preclinical findings suggest a mechanistic pathway by which this specific probiotic strain may modulate metabolic homeostasis in early obesity through SCFA production and enteroendocrine signaling. Clinical translation requires human trials to confirm efficacy, clarify SCFA-mediated causality, and address heterogeneous immune responses.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction The gut microbiota–enteroendocrine axis contributes to the regulation of host energy homeostasis through microbial metabolites and satiety-related signaling. This study evaluated whether Lactiplantibacillus pentosus CECT 8039 ( L. pentosus BB) modulates microbial fermentation, enteroendocrine responses, and metabolic and immune parameters associated with early diet-induced obesity. Methods A dynamic multi-compartment colonic fermentation model was used to assess changes in cultivable microbial groups and short-chain fatty acid (SCFA) concentrations following probiotic treatment. Fermentation samples were subsequently evaluated in STC-1 enteroendocrine cells and a Caco-2/THP-1 co-culture model. In parallel, the metabolic and immunomodulatory effects of L. pentosus BB were assessed in mice fed a high-fat diet (HFD) for 28 days. Results Probiotic treatment selectively modulated cultivable microbial groups, increasing lactic acid bacteria and decreasing Clostridium spp. across the three simulated colonic compartments, while other groups showed region-dependent changes. Acetate, propionate, and butyrate concentrations increased in all three compartments; in the ascending colon, they increased 2.53-, 7.34-, and 5.08-fold, respectively, relative to the end of stabilization. Fermentation samples collected after probiotic treatment increased GLP-1 release, reaching statistical significance in the transverse-colon condition, while Pyy mRNA expression increased significantly in the ascending and descending colon conditions and Cck expression increased significantly in all three compartments. In vivo, HFD-fed mice showed a 34.9 ± 5.5% body-weight gain, whereas probiotic supplementation was associated with a 13.2 ± 4.7% lower relative body-weight gain compared with the HFD control group. In HFD-fed mice, probiotic supplementation reduced circulating resistin by 25.8 ± 9.4% and leptin by 85.5 ± 20.1%, whereas the change in adiponectin was not statistically significant. Immune responses were heterogeneous and depended on the experimental context. Discussion L. pentosus BB was associated with increased colonic SCFA concentrations, enhanced enteroendocrine responses, and partial attenuation of HFD-associated metabolic alterations. These findings support a functional association between probiotic-modulated microbial fermentation and host endocrine and metabolic responses, although direct SCFA-mediated causality remains to be established.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.